Manitex Capital Inc. announced that its affiliate, Valeo Pharma Inc., has received approval from Health Canada for a new Parkinson's Disease product ONSTRY® (safinamide) in Canada. Valeo Pharma plans to launch ONSTRYV® in Canada in the first half of 2019. Already launched in Europe and the U.S.A., ONSTRYV® will provide an important new option to the estimated 100,000 Canadians living with Parkinson's Disease. Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality, sales and marketing, and distribution activities in Canada.